Organovo (ONVO) Reports Strong Customer Response Following Launch of ExVive Human Kidney Tissue
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Organovo Holdings, Inc. (NASDAQ: ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that it has received a strong customer response for its second tissue service, the ExViveTM Human Kidney Tissue. This kidney proximal tubule model was launched in September, and is a natural expansion of the Company’s preclinical product and service portfolio. Customers use Organovo’s 3D bioprinted kidney tissue to study the effects of drug exposure through toxicology panels and transporter studies. The Company already has multiple commercial orders from several customers, including with two, global, top 25 pharmaceutical companies.
“Nephrotoxicity is a key concern in drug development and the proximal tubule is the primary site of renal toxicity,” said Dr. Caroline Lee, senior director, Ardea Biosciences, Inc. “Specifically, transporters in the proximal tubule play a crucial role in the distribution and accumulation of drugs in the kidney. The ExVive Human Kidney Tissue provides an ideal means to study the impact of renal transporters on the disposition of drugs because it closely resembles native human kidney proximal tubule, with its polarized renal epithelial cells and tubulointerstitial interface and in particular its native expression level of transporters enabling formation of the transport network.” Ardea Biosciences, Inc. is a wholly-owned subsidiary of AstraZeneca PLC.
"At La Jolla Pharmaceutical Company, we incorporate in vitro models to assess nephrotoxicity in the preclinical stage of drug development,” said Dr. Andrew Seacat, director, preclinical development, La Jolla Pharmaceutical Company. “Early safety prediction of compounds is challenging and many drugs fail in the clinic because of renal toxicity. Organovo has developed an in vitro human kidney tissue model that allows for study of renal toxicity, biomarker expression, and overall cellular and tissue health following compound exposure. La Jolla currently utilizes the ExVive Human Kidney Tissue model to assess the renal impact of our compounds during development.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Skyline Medical (SKLN) Appoints New CEO, Board Member
- salesforce.com (CRM), AWS (AMZN) Enter Expanded Global Strategic Alliance
- B&G Foods (BGS) Acquires Victoria Fine Foods for $70M
Create E-mail Alert Related CategoriesCorporate News, Management Comments, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!